Needham on Lucid (LUCD): 'we remain positive on potential Medicare reimbursement of EsoGuard and we expect LUCD's revenue growth to improve'
Tweet Send to a Friend
Needham analyst Mike Matson reiterated a Buy rating and $2.50 price target on Lucid Diagnostics Inc (NASDAQ: LUCD)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
